Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy

International Journal of Radiation Biology

Volumn 82, Issue 10, 2006, Pages 699-757

  Arbeit, Jeffrey M ^a   Brown, J Martin ^b   Chao, K S Clifford ^c   Chapman, J Donald ^d   Eckelman, William C ^e   Fyles, Anthony W ^f   Giaccia, Amato J ^b   Hill, Richard P ^f   Koch, Cameron J ^g   Krishna, Murali Cherukuri ^h   Krohn, Kenneth A ⁱ   Lewis, Jason S ^a   Mason, Ralph P ^j   Melillo, Giovanni ^h   Padhani, Anwar R ^k   Powis, Garth ^l   Rajendran, Joseph G ^m   Reba, Richard ⁿ   Robinson, Simon P ^o   Semenza, Gregg L ^p   Swartz, Harold M ^q   Vaupel, Peter ^r   Yang, David ^c   Tatum, James L ^s   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CRM Consulting Services   (Canada)

^e Molecular Tracer LLC   (United States)

^f Ontario Cancer Institute   (Canada)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NCI   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k MOUNT VERNON HOSPITAL   (United Kingdom)

^l UNIVERSITY OF ARIZONA   (United States)

^m UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

ⁿ GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^o ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^p JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q DARTMOUTH MEDICAL SCHOOL   (United States)

^r JOHANNES GUTENBERG UNIVERSITY   (Germany)

^s NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

Hypoxia; Imaging; Tumour marker; Tumour physiology

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; BOVINE SERUM ALBUMIN; CARBONATE DEHYDRATASE IX; CHELATE; CONTRAST MEDIUM; COPPER DERIVATIVE; COPPER DIACETYLBIS(N 4 METHYLTHIOSEMICARBAZONE); FLUOROCARBON; GADODIAMIDE; GADOLINIUM PENTETATE; GADOMER 17; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; INTERLEUKIN 8; NITROIMIDAZOLE; OSTEOPONTIN; P 792; PIMONIDAZOLE; PROTEIN INHIBITOR; PX 478; SHU 555C; THIOSEMICARBAZONE DERIVATIVE; TIRAPAZAMINE; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; BRAIN CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER THERAPY; CLINICAL ASSESSMENT; CONFERENCE PAPER; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; ELECTRON SPIN RESONANCE; GOLD STANDARD; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMAGE ANALYSIS; IMAGING; MEASUREMENT; METASTASIS; MOLECULAR BIOLOGY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR OVERHAUSER EFFECT; OXIMETRY; OXYGEN BLOOD LEVEL; OXYGEN TENSION; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN TARGETING; RADIOSENSITIVITY; REOXYGENATION; RISK FACTOR; TISSUE OXYGENATION; TUMOR GROWTH; UTERINE CERVIX CANCER;

ANOXIA; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBONIC ANHYDRASES; DIAGNOSTIC IMAGING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; ISOENZYMES; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; OXYGEN; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 33751543273     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000601002324     Document Type: Conference Paper

References (337)

1. Abramovitch R, Dafni H, Smouha E, Benjamin LE, Neeman M. 1999. In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Research 59:5012-5016.
2. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL. 2001. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Research 61:2911-2916.
3. Aime S, Botta M, Gianolio E, Terreno E. 2000. A p(O(2))-responsive MRI contrast agent based on the redox switch of Manganese(II/III)-Porphyrin complexes. Angewandte Chemie (International Ed. in English) 39:747-750.
4. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I, West C. 2001. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clinical Cancer Research 7:928-934.
5. Al Hallaq HA, Fan X, Zamora M, River JN, Moulder JE, Karczmar GS. 2002. Spectrally inhomogeneous BOLD contrast changes detected in rodent tumors with high spectral and spatial resolution MRI. NMR in Biomedicine 15:28-36.
6. Al Hallaq HA, River JN, Zamora M, Oikawa H, Karczmar GS. 1998. Correlation of magnetic resonance and oxygen microelectrode measurements of carbogen-induced changes in tumor oxygenation. International Journal of Radiation Oncology, Biology, Physics 41:151-159.
7. Al Sobhi S, Ashari LH, Ingemansson S. 1999. Detection of metastatic parathyroid carcinoma with Tc-99m sestamibi imaging. Clinical Nuclear Medicine 24:21-23.
8. Anderson RF, Shinde SS, Hay MP, Gamage SA, Denny WA. 2003. Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. Journal of the American Chemical Society 125:748-756.
9. Aquino-Parsons C, Luo C, Vikse CM, Olive PL. 1999. Comparison between the comet assay and the oxygen microelectrode for measurement of tumor hypoxia. Radiotherapy and Oncology 51:179-185.
10. Arbeit JM. 2002. Quiescent hypervascularity mediated by gain of HIF-1 alpha function. Cold Spring Harbor Symposia on Quantitative Biology 67:133-142.
11. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. 2003. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proceedings of the National Academy of Sciences of the United States of America 100:10158-10163.
12. Atkin G, Taylor NJ, Daley FM, Stirling JJ, Richman P, Glynne-Jones R, d'Arcy JA, Collins DC, Padhani AR. 2006. Dynamic contrast-enhanced MRI (DCE-MRI) is a poor biomarker of rectal cancer angiogenesis. British Journal of Surgery May 93(8):992-1000.
13. Ballinger JR, Kee JW, Rauth AM. 1996. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. Journal of Nuclear Medicine 37:1023-1031.
14. Barnhart AJ, Voorhees WD, Green MA. 1989. Correlation of Cu(PTSM) localization with regional blood flow in the heart and kidney. International Journal of Radiation Applications and Instrumentation Part B 16:747-748.
15. Barthel H, Wilson H, Collingridge DR, Brown G, Osman S, Luthra SK, Brady F, Workman P, Price PM, Aboagye EO. 2004. In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. British Journal of Cancer 90:2232-2242.
16. Baudelet C, Gallez B. 2002. How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors? Magnetic Resonance in Medicine 48:980-986.
17. Bayes M, Rabasseda X, Prous JR. 2004. Gateways to clinical trials. Methods and Findings in Experimental and Clinical Pharmacology 26:211-244.
18. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S, Harris AL. 2002. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Research 62:2493-2497.
19. Beppu T, Kamada K, Yoshida Y, Arai H, Ogasawara K, Ogawa A. 2002. Change of oxygen pressure in glioblastoma tissue under various conditions. Journal of Neurooncology 58:47-52.
20. Bergers G, Benjamin LE. 2003. Tumorigenesis and the angiogenic switch. Nature Reviews Cancer 3:401-410.
21. Bhujwalla ZM, Artemov D, Ballesteros P, Cerdan S, Gillies RJ, Solaiyappan M. 2002. Combined vascular and extracellular pH imaging of solid tumors. NMR in Biomedicine 15:114-119.
22. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, Solaiyappan M. 2001. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 3:143-153.
23. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. 2001. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clinical Cancer Research 7:1661-1668.
24. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. 2000. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Research 60: 4693-4696.
25. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ. 2002. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clinical Cancer Research 8:1974-1983.
26. Bos R, Der Hoeven JJ, van der Wall E, van der GP, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CF. 2002. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. Journal of Clinical Oncology 20:379-387.
27. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E. 2003. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97:1573-1581.
28. Bourke V, Gilio J, Zhao D, Constantinescu A, Kodibager V, Jiang L, Hahn EW, Mason RP. 2004. Correlation of tumor oxygen dynamics with radiation response of the Dunning prostate R3327-AT1 tumor. Presented at the 51st Annual Meeting of the Radiation Research Society, St. Louis, MO.
29. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. 1999. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiotherapy and Oncology 53:113-117.
30. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. 1996. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Research 56:941-943.
31. Brown JM. 1993. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. British Journal of Cancer 67:1163-1170.
32. Brown JM. 2002. Tumor microenvironment and the response to anticancer therapy. Cancer Biology and Therapy 1:453-458.
33. Brown JM, Lemmon MJ. 1990. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Research 50:7745-7749.
34. Brown JM, Yu NY, Brown DM, Lee WW. 1981. SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. International Journal of Radiation Oncology, Biology, Physics 7:695-703.
35. Brune B, Zhou J. 2003. The role of nitric oxide (NO) in stability regulation of hypoxia inducible factor-1alpha (HIF-1alpha). Current Medicinal Chemistry 10:845-855.
36. Burai L, Scopelliti R, Toth E. 2002. EuII-cryptate with optimal water exchange and electronic relaxation: a synthon for potential pO2 responsive macromolecular MRI contrast agents. Chemical Communications (Cambridge, England) 20:2366-2367.
37. Burai L, Toth E, Seibig S, Scopelliti R, Merbach AE. 2000. Solution and solid-state characterization of Eu(II) chelates: a possible route towards redox responsive MRI contrast agents. Chemistry 6:3761-3770.
38. Cairns RA, Hill RP. 2004. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Research 64:2054-2061.
39. Cairns RA, Kalliomaki T, Hill RP. 2001. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Research 61:8903-8908.
40. Caravan P, Cloutier NJ, Greenfield MT, McDermid SA, Dunham SU, Bulte JW, Amedio JC Jr, Looby RJ, Supkowski RM, Horrocks WD Jr, McMurry TJ, Lauffer RB. 2002. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. Journal of the American Chemical Society 124:3152-3162.
41. Carnell DM, Taylor NJ, Smith RE, Hoskin PJ, Stirling JJ, d'Arcy JA, Walker-Samuel S, Collins DJ, Leach MO, Padhani AR. 2005. Evaluation of prostate gland hypoxia with quantified BOLD MRI: updated results from a correlated histological study. Abstract No 270. Proceedings of the International Society of Magnetic Resonance in Medicine, 13th Scientific Meeting and Exhibition, Miami FL.
42. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. 1996. Osteopontin expression in lung cancer. Lung Cancer 15:311-323.
43. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ. 2001. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. International Journal of Radiation Oncology, Biology, Physics 49:1171-1182.
44. Chapman JD. 1979. Hypoxic sensitizers - implications for radiation therapy. New England Journal of Medicine 301:1429-1432.
45. Chapman JD, Coia Lr, Stobbe CC, Engelhardt EL, Fenning MC, Schneider RF. 1996. Prediction of tumour hypoxia and radioresistance with nuclear medicine markers. British Journal of Cancer Supplement 27:S204-S208.
46. Chapman JD, Franko AJ, Sharplin J. 1981. A marker for hypoxic cells in tumours with potential clinical applicability. British Journal of Cancer 43:546-550.
47. Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR. 2003. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. British Journal of Cancer 89:1889-1895.
48. Chella A, Lucchi M, Ambrogi MC, Menconi G, Melfi FM, Gonfiotti A, Boni G, Angeletti CA. 2000. A pilot study of the role of TC-99 radionuclide in localization of pulmonary nodular lesions for thoracoscopic resection. European Journal of Cardio-thoracic Surgery 18:17-21.
49. Clark LC Jr, Ackerman J, Thomas SR, Millard RW, Hoffmann RE, Pratt RG, Ragle-Cole H, Kinsey RA, Janakiraman R. 1984. Perfluorinated organic liquids and emulsions as biocompatible NMR imaging agents for 19F and dissolved oxygen. In: Bruley D, Bicher HI, Reneau D, editors. Oxygen Transport to Tissue VI, New York: Plenum. pp 835-845.
50. Clavo B, Robaina F, Morera J, Ruiz-Egea E, Perez JL, Macias D, Carames MA, Catala L, Hernandez MA, Gunderoth M. 2002. Increase of brain tumor oxygenation during cervical spinal cord stimulation. Report of three cases. Journal of Neurosurgery Spine 96:94-100.
51. Collingridge DR, Piepmeier JM, Rockwell S, Knisely JP. 1999. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiotherapy and Oncology 53:127-131.
52. Cruickshank GS, Rampling RP, Cowans W. 1994. Direct measurement of the PO2 distribution in human malignant brain tumours. Advances in Experimental Medicine and Biology 345:465-470.
53. Cvetkovic D, Movsas B, Dicker AP, Hanlon AL, Greenberg RE, Chapman JD, Hanks GE, Tricoli JV. 2001. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 57:821-825.
54. d'Asseler YM, Koole M, Lemahieu I, Achten E, Boon P, De Deyn PP, Dierckx RA. 1997. Recent and future evolutions in NeuroSPECT with particular emphasis on the synergistic use and fusion of imaging modalities. Acta Neurologica Belgica 97:154-162.
55. Dafni H, Landsman L, Schechter B, Kohen F, Neeman M. 2002. MRI and fluorescence microscopy of the acute vascular response to VEGF165: vasodilation, hyper-permeability and lymphatic uptake, followed by rapid inactivation of the growth factor. NMR in Biomedicine 15:120-131.
56. Daldrup-Link HE, Shames DM, Wendland M, Muhler A, Gossmann A, Rosenau R, Brasch RC. 2000. Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging. Academic Radiology 7:934-944.
57. Daniels JS, Gates KS. 1996. DNA cleavage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR4233): Evidence for involvement of hydroxyl radical. Journal of the American Chemical Society 118:3380-3385.
58. Das R, Mahabeleshwar GH, Kundu GC. 2004. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. Journal of Biological Chemistry 279:11051-11064.
59. De Jaeger K, Kavanagh MC, Hill RP. 2001. Relationship of hypoxia to metastatic ability in rodent tumours. British Journal of Cancer 84:1280-1285.
60. Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ. 2002. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. Journal of Biological Inorganic Chemistry 7:249-259.
61. Degani H, Chetrit-Dadiani M, Bogin L, Furman-Haran E. 2003. Magnetic resonance imaging of tumor vasculature. Thrombosis and Haemostasis 89:25-33.
62. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. 2003a. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. International Journal of Radiation Oncology, Biology, Physics 55:1233-1238.
63. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA. 2003b. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. European Journal of Nuclear Medicine and Molecular Imaging 30:844-850.
64. Del Rowe J, Scott C, Werner-Wasik M, Bahary JP, Curran WJ, Urtasun RC, Fisher B. 2000. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. Journal of Clinical Oncology 18:1254-1259.
65. Delpuech J-J, Hamza MA, Serratice G, Stebe M-J. 1979. Fluorocarbons as oxygen carriers. I. An NMR study of oxygen solutions in hexafluorobenzene. Journal of Chemical Physics 70:2680-2687.
66. Dewhirst MW, Tso CY, Oliver R, Gustafson CS, Secomb TW, Gross JF. 1989. Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. International Journal of Radiation Oncology, Biology, Physics 17:91-99.
67. Doherty N, Hancock SL, Kaye S, Coleman CN, Shulman L, Marquez C, Mariscal C, Rampling R, Senan S, Roemeling RV. 1994. Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. International Journal of Radiation Oncology, Biology, Physics 29:379-382.
68. Dolbier WR Jr, Li AR, Koch CJ, Shiue CY, Kachur AV. 2001. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Applied Radiation and Isotopes 54:73-80.
69. Doll CM, Milosevic M, Pintilie M, Hill RP, Fyles AW. 2003. Estimating hypoxic status in human tumors: a simulation using Eppendorf oxygen probe data in cervical cancer patients. International Journal of Radiation Oncology, Biology, Physics 55:1239-1246.
70. Dorie MJ, Brown JM. 1993. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Research 53:4633-4636.
71. Dorie MJ, Brown JM. 1997. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemotherapy and Pharmacology 39:361-366.
72. Dunst J, Stadler P, Becker A, Kuhnt T, Lautenschlager C, Molls M, Haensgen G. 2001. Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlentherapie und Onkologie 177:469-473.
73. Durand RE. 1991. Keynote address: the influence of microenvironmental factors on the activity of radiation and drugs. International Journal of Radiation Oncology, Biology, Physics 20:253-258.
74. Durand RE, Olive PL. 1997. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiation Oncology Investigations 5:213-219.
75. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. 1999. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Current Topics in Microbiology and Immunology 237:97-132.
76. Earls JP, Bluemke DA. 1999. New MR imaging contrast agents. Magnetic Resonance Imaging Clinics of North America 7:255-273.
77. Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS, Arbeit JM. 2001. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes and Development 15:2520-2532.
78. Elwell JH, Siim BG, Evans JW, Brown JM. 1997. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Biochemical Pharmacology 54:249-257.
79. Engelhardt EL, Schneider RF, Seeholzer SH, Stobbe CC, Chapman JD. 2002. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia. Journal of Nuclear Medicine 43:837-850.
80. Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 1996. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Research 56:405-411.
81. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, Nelson PT, Lustig RA, Jenkins K, Magarelli DP, Hahn SM, Collins RA, Grady MS, Koch CJ. 2004a. Hypoxia is important in the biology and aggression of human glial brain tumors. Clinical Cancer Research 10:8177-8184.
82. Evans SM, Judy KD, Dunphy I, Jenkins WT, Nelson PT, Collins R, Wileyto EP, Jenkins K, Hahn SM, Stevens CW, Judkins AR, Phillips P, Geoerger B, Koch CJ. 2004b. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Research 64:1886-1892.
83. Falk SJ, Ward R, Bleehen NM. 1992. The influence of carbogen breathing on tumour tissue oxygenation in man evaluated by computerised p02 histography. British Journal of Cancer 66:919-924.
84. Feng D, Nagy JA, Hipp J, Dvorak HF, Dvorak AM. 1996. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. Journal of Experimental Medicine 183:1981-1986.
85. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. 1997. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. Journal of Nuclear Medicine 38: 1155-1160.
86. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. 2002. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. Journal of Biological Chemistry 277:38205-38211.
87. Fukuda R, Kelly B, Semenza GL. 2003. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Research 63:2330-2334.
88. Furman-Haran E, Margalit R, Maretzek AF, Degani H. 1996. Angiogenic response of MCF7 human breast cancer to hormonal treatment: assessment by dynamic GdDTPA-enhanced MRI at high spatial resolution. Journal of Magnetic Resonance Imaging 6:195-202.
89. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP. 2002. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. Journal of Clinical Oncology 20:680-687.
90. Gaillard S, Kubiak C, Stolz C, Bonnemain B, Chassard D. 2002. Safety and pharmacokinetics of p792, a new blood-pool agent: Results of clinical testing in nonpatient volunteers. Investigative Radiology 37:161-166.
91. Galbraith SM, Lodge MA, Taylor NJ, Rustin GJ, Bentzen S, Stirling JJ, Padhani AR. 2002. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: Comparison of quantitative and semi-quantitative analysis. NMR in Biomedicine 15:132-142.
92. Gallez B, Baudelet C, Jordan BF. 2004. Assessment of tumor oxygenation by electron paramagnetic resonance: Principles and applications. NMR in Biomedicine 17:240-262.
93. Garcia-Martin ML, Herigault G, Remy C, Farion R, Ballesteros P, Coles JA, Cerdan S, Ziegler A. 2001. Mapping extracellular pH in rat brain gliomas in vivo by 1H magnetic resonance spectroscopic imaging: Comparison with maps of metabolites. Cancer Research 61:6524-6531.
94. Garrecht BM, Chapman JD. 1983. The labelling of EMT-6 tumours in BALB/C mice with 14C-misonidazole. British Journal of Radiology 56:745-753.
95. Geyer RP. 1975. Bloodless rats through the use of artificial blood substitutes. Federation Proceedings 34:1499-1505.
96. Gillies RJ, Raghunand N, Garcia-Martin ML, Gatenby RA. 2004. pH imaging. A review of pH measurement methods and applications in cancers. IEEE Engineering in Medicine and Biology Magazine 23:57-64.
97. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. 2002. MRI of the tumor microenvironment. Journal of Magnetic Resonance Imaging 16:430-450.
98. Gokhale AS, Haddad RI, Cavacini LA, Wirth L, Weeks L, Hallar M, Faucher J, Posner MR. 2005. Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncology 41:70-76.
99. Golman K, Ardenkjaer-Larsen JH, Petersson JS, Mansson S, Leunbach I. 2003. Molecular imaging with endogenous substances. Proceedings of the National Academy of Sciences of the United States of America 100:10435-10439.
100. Graham MA, Senan S, Robin H Jr, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R, Workman P. 1997. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: Retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemotherapy and Pharmacology 40:1-10.
101. Grinberg OY, Smirnov AI, Swartz HM. 2001. High spatial resolution multi-site EPR oximetry. The use of convolution-based fitting method. Journal of Magnetic Resonance 152:247-258.
102. Grinberg VO, Smirnov AI, Grinberg OY, Grinberg SA, O'Hara JA, Swartz HM. 2005. Practical experimental conditions and limitations for high spatial resolution multi-site EPR oximetry. Applied Magnetic Resonance 28:69-78.
103. Gross S, Gilead A, Scherz A, Neeman M, Salomon Y. 2003. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nature Medicine 9:1327-1331.
104. Hall EJ. 2000. Radiobiology for the radiologist. Philadelphia: Lippincott Willams & Wilkins.
105. Hampel DJ, Sansome C, Romanov VI, Kowalski AJ, Denhardt DT, Goligorsky MS. 2003. Osteopontin traffic in hypoxic renal epithelial cells. Nephron Experimental Nephrology 94:e66-e76.
106. Haugland HK, Vukovic V, Pintilie M, Fyles AW, Milosevic M, Hill RP, Hedley DW. 2002. Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: Correlation with tumor oxygenation. International Journal of Radiation Oncology, Biology, Physics 53:854-861.
107. Hayes C, Padhani AR, Leach MO. 2002. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR in Biomedicine 15:154-163.
108. He G, Samouilov A, Kuppusamy P, Zweier JL. 2002. In vivo imaging of free radicals: Applications from mouse to man. Molecular and Cellular Biochemistry 234-235:359-367.
109. He Q, Xu RZ, Shkarin P, Pizzorno G, Lee-French CH, Rothman DL, Shungu DC, Shim H. 2003. Magnetic resonance spectroscopic imaging of tumor metabolic markers for cancer diagnosis, metabolic phenotyping, and characterization of tumor microenvironment. Disease Markers 19:69-94.
110. Hedley D, Pintilie M, Woo J, Morrison A, Birle D, Fyles A, Milosevic M, Hill R. 2003. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clinical Cancer Research 9:5666-5674.
111. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MA, Werb Z, Rafii S. 2002. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109:625-637.
112. Helbich TH, Roberts TP, Gossmann A, Wendland MF, Shames DM, Adachi M, Yang S, Huber S, Daldrup H, Brasch RC. 2000. Quantitative gadopentetate-enhanced MRI of breast tumors: testing of different analytic methods. Magnetic Resonance in Medicine 44:915-924.
113. Hill RP, De Jaeger K, Jang A, Cairns R. 2001. pH, hypoxia and metastasis. Novartis Foundation Symposium 240:154-165.
114. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. 1996. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research 56:4509-4515.
115. Hockel M, Vaupel P. 2001a. Biological consequences of tumor hypoxia. Seminars in Oncology 28:36-41.
116. Hockel M, Vaupel P. 2001b. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute 93:266-276.
117. Hockel S, Schlenger K, Vaupel P, Hockel M. 2001. Association between host tissue vascularity and the prognostically relevant tumor vascularity in human cervical cancer. International Journal of Oncology 19:827-832.
118. Hoffman JM, Rasey JS, Spence AM, Shaw DW, Krohn KA. 1987. Binding of the hypoxia tracer [3H]misonidazole in cerebral ischemia. Stroke 18:168-176.
119. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H. 2001. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. European Journal of Nuclear Medicine 28:1751-1757.
120. Hohenberger P, Bida B, Schlag PM. 1996. Alteration of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or recombinant human tumor necrosis factor alpha combined with melphalan. Strahlentherapie und Onkologie 172 Suppl 2:14-15.
121. Horowitz M, Blasberg R, Molnar P, Strong J, Kornblith P, Pleasants R, Fenstermacher J. 1983. Regional [14C]misonidazole distribution in experimental RT-9 brain tumors. Cancer Research 43:3800-3807.
122. Hou H, Khan N, O'Hara JA, Grinberg OY, Dunn JF, Abajian MA, Wilmot CM, Makki M, Demidenko E, Lu S, Steffen RP, Swartz HM. 2004. Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study. International Journal of Radiation Oncology, Biology, Physics 59:834-843.
123. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR. 2001. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR in Biomedicine 14:497-506.
124. Howe FA, Robinson SP, Rodrigues LM, Griffiths JR. 1999. Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumors to carbogen breathing. Magnetic Resonance Imaging 17:1307-1318.
125. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, Gatter KC, Johnson PJ, Harris AL. 2002. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clinical Cancer Research 8:2595-2604.
126. Hunjan S, Zhao D, Constantinescu A, Hahn EW, Antich PP, Mason RP. 2001. Tumor oximetry: demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging in the Dunning prostate R3327-AT1 rat tumor. International Journal of Radiation Oncology, Biology, Physics 49:1097-1108.
127. Jackson SK, Thomas MP, Smith S, Madhani M, Rogers SC, James PE. 2004. In vivo EPR spectroscopy: biomedical and potential diagnostic applications. Faraday Discussions 126:103-117.
128. James PE, Thomas MP, Jackson SK. 2004. Tissue oxygenation in sepsis; new insights from in vivo EPR. NMR in Biomedicine 17:319-326.
129. Jette DC, Wiebe LI, Flanagan RJ, Lee J, Chapman JD. 1986. Iodoazomycin riboside (1-(5′-iodo-5′-deoxyribofuranosyl)-2-nitroimidazole), a hypoxic cell marker. I. Synthesis and in vitro characterization. Radiation Research 105:169-179.
130. Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis G, Gillies RJ. 2005. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 7:475-485.
131. Joseph P, Jaiswal AK, Stobbe CC, Chapman JD. 1994. The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. International Journal of Radiation Oncology, Biology, Physics 29:351-355.
132. Joseph PM, Fishman JE, Mukherji B, Sloviter HA. 1985. In vivo 19F NMR imaging of the cardiovascular system. Journal of Computer Assisted Tomography 9:1012-1019.
133. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. 2003. Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein. Journal of Biological Chemistry 278:7445-7452.
134. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, de Wilde PC, Bussink J, Raleigh JA, van der Kogel AJ. 2002. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Research 62:7066-7074.
135. Kallinowski F, Eble MJ, Buhr HJ, Wannenmacher M, Herfarth C. 1995. Intraoperative radiotherapy for primary and recurrent rectal cancer. European Journal of Surgical Oncology 21:191-194.
136. Kallinowski F, Zander R, Hoeckel M, Vaupel P. 1990. Tumor tissue oxygenation as evaluated by computerized-pO2-histography. International Journal of Radiation Oncology, Biology, Physics 19:953-961.
137. Karam JA, Mason RP, Koeneman KS, Antich PP, Benaim EA, Hsieh JT. 2003. Molecular imaging in prostate cancer. Journal of Cellular Biochemistry 90:473-483.
138. Kavanagh MC, Tsang V, Chow S, Koch C, Hedley D, Minkin S, Hill RP. 1999. A comparison in individual murine tumors of techniques for measuring oxygen levels. International Journal of Radiation Oncology, Biology, Physics 44:1137-1146.
139. Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA, Semenza GL. 2003. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circulation Research 93:1074-1081.
140. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L. 2000. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clinical and Experimental Metastasis 18:261-271.
141. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, Hong K, Dewhirst MW. 1996. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Research 56:5522-5528.
142. Knocke TH, Weitmann HD, Feldmann HJ, Selzer E, Potter R. 1999. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiotherapy and Oncology 53:99-104.
143. Knopp MV, Giesel FL, Marcos H, Tengg-Kobligk H, Choyke P. 2001. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Topics in Magnetic Resonance Imaging 12:301-308.
144. Koch CJ. 1993. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Research 53:3992-3997.
145. Koch CJ. 2002. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods in Enzymology 352:3-31.
146. Koch CJ, Evans SM, Lord EM. 1995. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide]: Analysis of drug adducts by fluorescent antibodies vs bound radioactivity. British Journal of Cancer 72:869-874.
147. Koch CJ, Hahn SM, Rockwell K Jr, Covey JM, McKenna WG, Evans SM. 2001. Pharmacokinetics of EF5 [2-(2-nitro-1-Himidazol-1-yl)-N-(2,2,3,3,3- pentafluoropropyl) acetamide] in human patients: Implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemotherapy and Pharmacology 48:177-187.
148. 1H NMR approach to quantitative tissue oximetry using hexamethyldisiloxane. Magnetic Resonance in Medicine 55:743-748.
149. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, Grierson JR, Lindsley KL, Lewellen TK, Krohn KA, Griffin TW. 1995. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. International Journal of Radiation Oncology, Biology, Physics 33:391-398.
150. Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, Bastidas AJ, Vierra M. 2000. Pancreatic tumors show high levels of hypoxia. International Journal of Radiation Oncology, Biology, Physics 48:919-922.
151. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, Gatter KC, Harris AL. 2001. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clinical Cancer Research 7:3399-3403.
152. Kovacs MS, Hocking DJ, Evans JW, Siim BG, Wouters BG, Brown JM. 1999. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. British Journal of Cancer 80:1245-1251.
153. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. 2000. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19:5435-5443.
154. Krishna MC, Devasahayam N, Cook JA, Subramanian S, Kuppusamy P, Mitchell JB. 2001a. Electron paramagnetic resonance for small animal imaging applications. ILAR Journal 42:209-218.
155. Krishna MC, English S, Yamada K, Yoo J, Murugesan R, Devasahayam N, Cook JA, Golman K, Ardenkjaer-Larsen JH, Subramanian S, Mitchell JB. 2002. Overhauser enhanced magnetic resonance imaging for tumor oximetry: coregistration of tumor anatomy and tissue oxygen concentration. Proceedings of the National Academy of Sciences of the United States of America 99:2216-2221.
156. Krishna MC, Subramanian S, Kuppusamy P, Mitchell JB. 2001b. Magnetic resonance imaging for in vivo assessment of tissue oxygen concentration. Seminars in Radiation Oncology 11:58-69.
157. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, Semenza GL. 2003. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Research 63:1138-1143.
158. Lartigau E, Randrianarivelo H, Avril MF, Margulis A, Spatz A, Eschwege F, Guichard M. 1997. Intratumoral oxygen tension in metastatic melanoma. Melanoma Research 7:400-406.
159. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. 2001. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Molecular and Cellular Biology 21:3995-4004.
160. Le D, Mason RP, Hunjan S, Constantinescu A, Barker BR, Antich PP. 1997. Regional tumor oxygen dynamics: 19F PBSR EPI of hexafluorobenzene. Magnetic Resonance Imaging 15:971-981.
161. Le QT, Kovacs MS, Dorie MJ, Koong A, Terris DJ, Pinto HA, Goffinet DR, Nowels K, Bloch D, Brown JM. 2003a. Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. International Journal of Radiation Oncology, Biology, Physics 56:375-383.
162. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ. 2003b. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clinical Cancer Research 9:59-67.
163. Lee DJ, Trotti A, Spencer S, Rostock R, Fisher C, von Roemeling R, Harvey E, Groves E. 1998. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. International Journal of Radiation Oncology, Biology, Physics 42:811-815.
164. Lewis JS, Herrero P, Sharp TL, Engelbach JA, Fujibayashi Y, Laforest R, Kovacs A, Gropler RJ, Welch MJ. 2002. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone). Journal of Nuclear Medicine 43:1557-1569.
165. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. 1999. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. Journal of Nuclear Medicine 40:177-183.
166. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. 2001. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): Effect of changes in tissue oxygenation. Journal of Nuclear Medicine 42:655-661.
167. Li P, Oparil S, Feng W, Chen YF. 2004. Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells. Journal of Applied Physiology 97:1550-1558.
168. Liptay MJ, Masters GA, Winchester DJ, Edelman BL, Garrido BJ, Hirschtritt TR, Perlman RM, Fry WA. 2000. Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer. Annals of Thoracic Surgery 70:384-389.
169. Ljunggren K, Strand SE. 1990. Beta camera for static and dynamic imaging of charged-particle emitting radionuclides in biologic samples. Journal of Nuclear Medicine 31:2058-2063.
170. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CM. 2001. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Research 61:6394-6399.
171. Lord EM, Harwell L, Koch CJ. 1993. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Research 53:5721-5726.
172. Lu ZR, Parker DL, Goodrich KC, Wang X, Dalle JG, Buswell HR. 2004. Extracellular biodegradable macromolecular gadolinium(III) complexes for MRI. Magnetic Resonance in Medicine 51:27-34.
173. Lu ZR, Wang X, Parker DL, Goodrich KC, Buswell HR. 2003. Poly(l-glutamic acid) Gd(III)-DOTA conjugate with a degradable spacer for magnetic resonance imaging. Bioconjugate Chemistry 14:715-719.
174. Lukiw WJ, Ottlecz A, Lambrou G, Grueninger M, Finley J, Thompson HW, Bazan NG. 2003. Coordinate activation of HIF-1 and NF-kappaB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Investigative Ophthalmology and Visual Science 44:4163-4170.
175. Lyng H, Sundfor K, Trope C, Rofstad EK. 2000. Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. Clinical Cancer Research 6:1104-1112.
176. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2003. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3:363-375.
177. Macpherson GR, Figg WD. 2004. Small molecule-mediated anticancer therapy via Hypoxia-Inducible Factor-1 blockade. Cancer Biology and Therapy 3:503-504.
178. Mannan RH, Mercer JR, Wiebe LI, Kumar P, Somayaji VV, Chapman JD. 1992. Radioiodinated azomycin pyranoside (IAZP): a novel non-invasive marker for the assessment of tumor hypoxia. Journal of Nuclear Biology and Medicine 36:60-67.
179. Martin GV, Caldwell JH, Rasey JS, Grunbaum Z, Cerqueira M, Krohn KA. 1989. Enhanced binding of the hypoxic cell marker [3H]fluoromisonidazole in ischemic myocardium. Journal of Nuclear Medicine 30:194-201.
180. Mason RP. 1994. Non-invasive physiology: 19F NMR of perfluorocarbons. Artificial Cells, Blood Substitutes and Immobilization Biotechnology 22:1141-1153.
181. Mason RP, Antich PP, Babcock EE, Constantinescu A, Peschke P, Hahn EW. 1994. Non-invasive determination of tumor oxygen tension and local variation with growth. International Journal of Radiation Oncology, Biology, Physics 29:95-103.
182. Mason RP, Antich PP, Babcock EE, Gerberich JL, Nunnally RL. 1989. Perfluorocarbon imaging in vivo: a 19F MRI study in tumor-bearing mice. Magnetic Resonance Imaging 7:475-485.
183. Mason RP, Constantinescu A, Hunjan S, Le D, Hahn EW, Antich PP, Blum C, Peschke P. 1999. Regional tumor oxygenation and measurement of dynamic changes. Radiation Research 152:239-249.
184. Mason RP, Hunjan S, Constantinescu A, Song Y, Zhao D, Hahn EW, Antich PP, Peschke P. 2003. Tumor oximetry: comparison of 19F MREPI and electrodes. In: Swartz HM, Dunn JF, editors. Oxygen Transport to Tissue XXIV. New York: Plenum. pp 19-28.
185. Mason RP, Ran S, Thorpe PE. 2002. Quantitative assessment of tumor oxygen dynamics: molecular imaging for prognostic radiology. Journal of Cellular Biochemistry Supplement 39:45-53.
186. Mason RP, Rodbumrung W, Antich PP. 1996. Hexafluorobenzene: A sensitive 19F NMR indicator of tumor oxygenation. NMR in Biomedicine 9:125-134.
187. Masuda K, Ono M, Okamoto M, Morikawa W, Otsubo M, Migita T, Tsuneyoshi M, Okuda H, Shuin T, Naito S, Kuwano M. 2003. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells. International Journal of Cancer 105:803-810.
188. Mattern J, Kallinowski F, Herfarth C, Volm M. 1996. Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer. International Journal of Cancer 67:20-23.
189. Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GE. 2002. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. Journal of Medicine and Chemistry 45:1420-1431.
190. Maxwell PH. 2004. HIF-1's relationship to oxygen: simple yet sophisticated. Cell Cycle 3:156-159.
191. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. 1999a. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275.
192. Maxwell RJ, Robinson SP, McIntyre DJ, Griffiths JR, Vojnovic B. 1999b. Comparison of changes in gradient echo 1H MR image intensity and pO2 in rodent tumours in response to carbogen breathing. Proceedings of the 7th International Society of Magnetic Resonance in Medicine, 495.
193. Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, Tozer GM. 2002. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR in Biomedicine 15:89-98.
194. McCarthy DW, Bass LA, Cutler PD, Shefer RE, Klinkowstein RE, Herrero P, Lewis JS, Cutler CS, Anderson CJ, Welch MJ. 1999. High purity production and potential applications of copper-60 and copper-61. Nuclear Medicine and Biology 26:351-358.
195. McDonald DM, Choyke PL. 2003. Imaging of angiogenesis: From microscope to clinic. Nature Medicine 9:713-725.
196. McIntyre DJO, McCoy CL, Griffiths JR. 1999. Tumour oxygenation measurements by 19F MRI of perfluorocarbons. Current Science 76:753-762.
197. McKenna D, Iqbal A, O'keeffe D. 2004. Tc-99m methylene diphosphonate uptake in a primary lung cancer. Clinical Nuclear Medicine 29:723-724.
198. Medico E, Gentile A, Lo CC, Williams TA, Gambarotta G, Trusolino L, Comoglio PM. 2001. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Research 61:5861-5868.
199. Milosevic M, Fyles A, Hill R. 2001. Interstitial fluid pressure in cervical cancer: Guide to targeted therapy. American Journal of Clinical Oncology 24:516-521.
200. Minet E, Michel G, Mottet D, Raes M, Michiels C. 2001. Transduction pathways involved in hypoxia-inducible factor-1 phosphorylation and activation. Free Radical Biology and Medicine 31:847-855.
201. Mishima H, Kobayashi T, Shimizu M, Tamaki Y, Baba M, Shimano T, Itoh S, Yamazaki M, Iriguchi N, Takahashi M, et al. 1991. In vivo F-19 chemical shift imaging with FTPA and antibody-coupled FMIQ. Journal of Magnetic Resonance Imaging 1:705-709.
202. Morawski AM, Winter PM, Yu X, Fuhrhop RW, Scott MJ, Hockett F, Robertson JD, Gaffney PJ, Lanza GM, Wickline SA. 2004. Quantitative magnetic resonance immunohistochemistry with ligand-targeted (19)F nanoparticles. Magnetic Resonance in Medicine 52:1255-1262.
203. Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, Hanks GE, Pollack A. 2002. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: Preliminary findings. Urology 60:634-639.
204. Movsas B, Chapman JD, Horwitz EM, Pinover WH, Greenberg RE, Hanlon AL, Iyer R, Hanks GE. 1999. Hypoxic regions exist in human prostate carcinoma. Urology 53:11-18.
205. Neckers L. 2003. Development of small molecule Hsp90 inhibitors: Utilizing both forward and reverse chemical genomics for drug identification. Current Medicinal Chemistry 10:733-739.
206. Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, Horsman MR, Overgaard J. 2001. Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations. British Journal of Cancer 84:1070-1075.
207. Nordsmark M, Overgaard J. 2000. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiotherapy and Oncology 57:39-43.
208. O'Hara JA, Blumenthal RD, Grinberg OY, Demidenko E, Grinberg S, Wilmot CM, Taylor AM, Goldenberg DM, Swartz HM. 2001. Response to radioimmunotherapy correlates with tumor pO2 measured by EPR oximetry in human tumor xenografts. Radiation Research 155:466-473.
209. O'Hara JA, Goda F, Demidenko E, Swartz HM. 1998. Effect on regrowth delay in a murine tumor of scheduling split-dose irradiation based on direct pO2 measurements by electron paramagnetic resonance oximetry. Radiation Research 150:549-556.
210. O-Charoenrat P, Rhys-Evans P, Eccles SA. 2001. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 92:556-568.
211. Ogan MD, Schmiedl U, Moseley ME, Grodd W, Paajanen H, Brasch RC. 1987. Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: Preparation and characterization. Investigative Radiology 22:665-671.
212. Oliver RJ, Woodwards RT, Sloan P, Thakker NS, Stratford IJ, Airley RE. 2004. Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection: Results of EORTC Translational Research Fund studies. European Journal of Cancer 40:503-507.
213. Os-Corby DJ, Chapman JD. 1986. In vitro binding of 14C-misonidazole to hepatocytes and hepatoma cells. International Journal of Radiation Oncology, Biology, Physics 12:1251-1254.
214. Os-Corby DJ, Koch CJ, Chapman JD. 1987. Is misonidazole binding to mouse tissues a measure of cellular pO2? Biochemical Pharmacology 36:3487-3494.
215. Padhani AR. 2002. Functional MRI for anticancer therapy assessment. European Journal of Cancer 38:2116-2127.
216. Padhani AR, Ah-See MLW, Taylor NJ, Stirling JJ, Daley FM, Richman PI, d'Arcy JA, Walker-Samuel S, Harris AL, Collins DJ, Leach MO, Makris A. 2005. An investigation of histological and DCE-MRI correlates of intrinsic susceptibility contrast relaxivity (R2*) in human breast cancer. Poster Presentation No. 1845. Proceedings of the International Society of Magnetic Resonance in Medicine, 13th Scientific Meeting and Exhibition, Miami FL.
217. Padhani AR, Taylor NJ, Lankester KJ, Ah-See MW, Atkin G, Carnell DM, Stirling JJ, Glynne-Jones R, Makris A, Hoskin PJ, d'Arcy JA, Leach MO, Rustin GJS. 2004. Heterogeneity of angiogenesis on DCE-MRI in human tumours: Implications for antiangiogenic therapies. Poster Presentation No. 1989. Proceedings of the International Society of Magnetic Resonance in Medicine, 12th Scientific Meeting, Kyoto Japan.
218. Padhani AR, Hayes C, Landau S, Leach MO. 2002. Reproducibility of quantitative dynamic MRI of normal human tissues. NMR in Biomedicine 15:143-153.
219. Padhani AR, Neeman M. 2001. Challenges for imaging angiogenesis. British Journal of Radiology 74:886-890.
220. Parker C, Milosevic M, Toi A, Sweet J, Panzarella T, Bristow R, Catton C, Catton P, Crook J, Gospodarowicz M, McLean M, Warde P, Hill RP. 2004. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics 58:750-757.
221. Parliament MB, Chapman JD, Urtasun RC, McEwan AJ, Golberg L, Mercer JR, Mannan RH, Wiebe LI. 1992. Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. British Journal of Cancer 65:90-95.
222. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. 1998. FDG accumulation and tumor biology. Nuclear Medicine and Biology 25:317-322.
223. Peschke P, Hahn EW, Wenz F, Lohr F, Braunschweig F, Wolber G, Zuna I, Wannenmacher M. 1998. Differential sensitivity of three sublines of the rat Dunning prostate tumor system R3327 to radiation and/or local tumor hyperthermia. Radiation Research 150:423-430.
224. Peters KB, Brown JM. 2002. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Research 62:5248-5253.
225. Pichiule P, Chavez JC, LaManna JC. 2004. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. Journal of Biological Chemistry 279:12171-12180.
226. Port M, Corot C, Raynal I, Idee JM, Dencausse A, Lancelot E, Meyer D, Bonnemain B, Lautrou J. 2001a. Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. Investigative Radiology 36:445-454.
227. Port RE, Knopp MV, Brix G. 2001b. Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. Magnetic Resonance in Medicine 45:1030-1038.
228. Quintero M, Mackenzie N, Brennan PA. 2004. Hypoxia-inducible factor 1 (HIF-1) in cancer. European Journal of Surgical Oncology 30:465-468.
229. Raghunand N, Gatenby RA, Gillies RJ. 2003a. Microenvironmental and cellular consequences of altered blood flow in tumours. British Journal of Radiology 76 (Suppl. 1):S11-S22.
230. Raghunand N, Gillies RJ. 2001. pH and chemotherapy. Novartis Foundation Symposium 240:199-211.
231. Raghunand N, Howison C, Sherry AD, Zhang S, Gillies RJ. 2003b. Renal and systemic pH imaging by contrast-enhanced MRI. Magnetic Resonance in Medicine 49:249-257.
232. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA. 2004. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clinical Cancer Research 10:2245-2252.
233. Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, Chin LK, Hofstrand PD, Grierson JR, Eary JF, Krohn KA. 2003. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. European Journal of Nuclear Medicine and Molecular Imaging 30:695-704.
234. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, Workman P. 1994. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. International Journal of Radiation Oncology, Biology, Physics 29:427-431.
235. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE. 1998. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Research 58:4646-4653.
236. Rapisarda A, Shoemaker RH, Melillo G. 2004a. Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle 3:172-175.
237. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. 2004b. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Research 64:1475-1482.
238. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt SM, Shoemaker RH, Melillo G. 2004c. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Research 64:6845-6848.
239. Rasey JS, Hofstrand PD, Chin LK, Tewson TJ. 1999. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. Journal of Nuclear Medicine 40:1072-1079.
240. Ravi D, Ramadas K, Mathew BS, Panikkar KR, Nair MK, Pillai MR. 2001. Apoptosis, angiogenesis and proliferation: trifunctional measure of tumour response to radiotherapy for oral cancer. Oral Oncology 37:164-171.
241. Riedel F, Gotte K, Schwalb J, Wirtz H, Bergler W, Hormann K. 2000. Serum levels of vascular endothelial growth factor in patients with head and neck cancer. European Archives of Otorhinolaryngology 257:332-336.
242. Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A. 2002. Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging. International Journal of Radiation Oncology, Biology, Physics 53:1185-1191.
243. Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, Jackson M, Kenny L, Penniment M, Corry J, Lamb D, McClure B. 2005. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). Journal of Clinical Oncology 23: 79-87.
244. Rischin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, Sexton M, D'Costa I, von Roemeling R. 2001. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. Journal of Clinical Oncology 19:535-542.
245. Roberts TP. 1997. Physiologic measurements by contrast-enhanced MR imaging: Expectations and limitations. Journal of Magnetic Resonance Imaging 7:82-90.
246. Robinson SP, Collingridge DR, Howe FA, Rodrigues LM, Chaplin DJ, Griffiths JR. 1999. Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR in Biomedicine 12:98-106.
247. Robinson SP, Kalber TL, Howe FA, McIntyre DJO, Griffiths JR, Blakey DC, Whittaker L, Ryan AJ, Waterton JC. 2005. Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Neoplasia 7:466-474.
248. Robinson SP, Rodrigues LM, Ojugo AS, McSheehy PM, Howe FA, Griffiths JR. 1997. The response to carbogen breathing in experimental tumour models monitored by gradient-recalled echo magnetic resonance imaging. British Journal of Cancer 75:1000-1006.
249. Rodrigues LM, Howe FA, Griffiths JR, Robinson SP. 2004. Tumor R2* is a prognostic indicator of acute radiotherapeutic response in rodent tumors. Journal of Magnetic Resonance Imaging 19:482-488.
250. Rudat V, Vanselow B, Wollensack P, Bettscheider C, Osman-Ahmet S, Eble MJ, Dietz A. 2000. Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer. Radiotherapy and Oncology 57:31-37.
251. Rudland PS, Platt-Higgins A, El Tanani M, De Silva RS, Barraclough R, Winstanley JH, Howitt R, West CR. 2002. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Research 62:3417-3427.
252. Runkel S, Wischnik A, Teubner J, Kaven E, Gaa J, Melchert F. 1994. Oxygenation of mammary tumors as evaluated by ultrasound-guided computerized-pO2-histography. Advances in Experimental Medicine and Biology 345:451-458.
253. Saha GB, MacIntyre WJ, Go RT. 1992. Cyclotrons and positron emission tomography radiopharmaceuticals for clinical imaging. Seminars in Nuclear Medicine 22:150-161.
254. Sanchez-Crespo A, Andreo P, Larsson SA. 2004. Positron flight in human tissues and its influence on PET image spatial resolution. European Journal of Nuclear Medicine and Molecular Imaging 31:44-51.
255. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM. 1998. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. Journal of Cell Biology 141:1083-1093.
256. Schindl M, Oberhuber G, Pichlbauer EG, Obermair A, Birner P, Kelley MR. 2001. DNA repair-redox enzyme apurinic endonuclease in cervical cancer: evaluation of redox control of HIF-1alpha and prognostic significance. International Journal of Oncology 19:799-802.
257. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G. 2002. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clinical Cancer Research 8:1831-1837.
258. Schirner M, Menrad A, Stephens A, Frenzel T, Hauff P, Licha K. 2004. Molecular imaging of tumor angiogenesis. Annals of the New York Academy of Sciences 1014:67-75.
259. Schmiedl U, Brasch RC, Ogan MD, Moseley ME. 1990. Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool and perfusion imaging. Acta Radiologica Supplement 374:99-102.
260. Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Holscher AH, Danenberg PV. 2004. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clinical Cancer Research 10:1588-1596.
261. Schornack PA, Gillies RJ. 2003. Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. Neoplasia 5:135-145.
262. Schuhmacher J, Kaul S, Klivenyi G, Junkermann H, Magener A, Henze M, Doll J, Haberkorn U, Amelung F, Bastert G. 2001. Immunoscintigraphy with positron emission tomography: Gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Research 61:3712-3717.
263. Schuster DP, Markham J, Welch MJ. 1998. Positron emission tomography measurements of pulmonary vascular permeability with Ga-68 transferrin or C-11 methylalbumin. Critical Care Medicine 26:518-525.
264. Sealy RC, Swartz HM, Olive PL. 1978. Electron spin resonance-spin trapping. Detection of superoxide formation during aerobic microsomal reduction of nitro-compounds. Biochemical and Biophysical Research Communications 82:680-684.
265. Secomb TW, Hsu R, Braun RD, Dewhirst MW. 1999. Analysis of oxygen transport to tumors: causes of heterogeneous tissue oxygenation. In: Goel VK, Spilker RL, Ateshian GA, Soslowsky LJ, editors. Proceedings of the 1999 Bioengineering Conference. New York. pp. 487-488.
266. Semenza GL. 2000. Expression of hypoxia-inducible factor 1: Mechanisms and consequences. Biochemical Pharmacology 59:47-53.
267. Semenza GL. 2001a. HIF-1 and mechanisms of hypoxia sensing. Current Opinion in Cell Biology 13:167-171.
268. Semenza GL. 2001b. Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. Pediatric Research 49:614-617.
269. Semenza GL. 2002. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends in Molecular Medicine 8:S62-S67.
270. Semenza GL. 2003. Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 3:721-732.
271. Sentjurc M, Cemazar M, Sersa G. 2004. EPR oximetry of tumors in vivo in cancer therapy. Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy 60:1379-1385.
272. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K. 1999. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clinical Cancer Research 5:3711-3721.
273. Shijubo N, Uede T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M, Abe S. 1999. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. American Journal of Respiratory and Critical CareMedicine 160:1269-1273.
274. Shulman LN, Buswell L, Riese N, Doherty N, Loeffler JS, von Roemeling RW, Coleman CN. 1999. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. International Journal of Radiation Oncology, Biology, Physics 44:349-353.
275. Simon R, Altman DG. 1994. Statistical aspects of prognostic factor studies in oncology. British Journal of Cancer 69:979-985.
276. Smirnov AI, Norby SW, Clarkson RB, Walczak T, Swartz HM. 1993. Simultaneous multi-site EPR spectroscopy in vivo. Magnetic Resonance in Medicine 30:213-220.
277. Song Y, Constantinescu A, Mason RP. 2002. Dynamic breast tumor oximetry: The development of prognostic radiology. Technology in Cancer Research and Treatment 1:471-478.
278. Stadler P, Becker A, Feldmann HJ, Hansgen G, Dunst J, Wurschmidt F, Molls M. 1999. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. International Journal of Radiation Oncology, Biology, Physics 44:749-754.
279. Stratford IJ, Adams GE, Bremner JC, Cole S, Edwards HS, Robertson N, Wood PJ. 1994. Manipulation and exploitation of the tumour environment for therapeutic benefit. International Journal of Radiation Biology 65:85-94.
280. Su MY, Cheung YC, Fruehauf JP, Yu H, Nalcioglu O, Mechetner E, Kyshtoobayeva A, Chen SC, Hsueh S, McLaren CE, Wan YL. 2003. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. Journal of Magnetic Resonance Imaging 18:467-477.
281. Su MY, Wang Z, Carpenter PM, Lao X, Muhler A, Nalcioglu O. 1999a. Characterization of N-ethyl-N-nitrosourea-induced malignant and benign breast tumors in rats by using three MR contrast agents. Journal of Magnetic Resonance Imaging 9:177-186.
282. Su MY, Wang Z, Nalcioglu O. 1999b. Investigation of longitudinal vascular changes in control and chemotherapy-treated tumors to serve as therapeutic efficacy predictors. Journal of Magnetic Resonance Imaging 9:128-137.
283. Subramanian S, Matsumoto K, Mitchell JB, Krishna MC. 2004. Radio frequency continuous-wave and time-domain EPR imaging and Overhauser-enhanced magnetic resonance imaging of small animals: instrumental developments and comparison of relative merits for functional imaging. NMR in Biomedicine 17:263-294.
284. Swartz HM. 2003a. Potential medical (clinical) applications of EPR: overview and perspectives. In: Berliner LJ, editor. In vivo EPR (ESR): Theory and applications. New York: Kluwer Academic/Plenum. pp 600-622.
285. Swartz HM. 2003b. The measurement of oxygen in vivo using EPR techniques. In: Berliner LJ, editor. In vivo EPR (ESR): Theory and applications. New York: Kluwer Academic/Plenum. pp 404-440.
286. Swartz HM, Clarkson RB. 1998. The measurement of oxygen in vivo using EPR techniques. Physics in Medicine and Biology 43:1957-1975.
287. Swartz HM, Dunn JF. 2003a. Measurements of oxygen in tissues: Overview and perspectives on methods. In: Swartz HM, Dunn JF, editors. Oxygen transport to tissue XXIV. New York: Plenum. pp 1-12.
288. Swartz HM, Dunn JF. 2003b. Measurements of oxygen in tissues: Overview and perspectives on methods. Advances in Experimental Medicine and Biology 530:1-12.
289. Swartz HM, Dunn JF. 2005. The difficulties in comparing in vivo oxygen measurements: Turning the problems into benefits. In: Okunieff P, Williams J,
290. Swartz HM, Khan N, Buckey J, Comi R, Gould L, Grinberg O, Hartford A, Hopf H, Hou H, Hug E, Iwasaki A, Lesniewski P, Salikhov I, Walczak T. 2004. Clinical applications of EPR: Overview and perspectives. NMR in Biomedicine 17:335-351.
291. Tannock IF. 1986. Experimental chemotherapy and concepts related to the cell cycle. International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine 49:335-355.
292. Taylor NJ, Baddeley H, Goodchild KA, Powell ME, Thoumine M, Culver LA, Stirling JJ, Saunders MI, Hoskin PJ, Phillips H, Padhani AR, Griffiths JR. 2001. BOLD MRI of human tumor oxygenation during carbogen breathing. Journal of Magnetic Resonance Imaging 14:156-163.
293. Terris DJ. 2000. Head and neck cancer: the importance of oxygen. The Laryngoscope 110:697-707.
294. Thomas SR. 1988. The biomedical applications of fluorine-19 NMR. In: Partain CL, Price RR, Patton JA, Kulkarni MV, James AEJ, editors. Magnetic Resonance Imaging. London: WB Saunders. pp 1536-1552.
295. Thomlinson RH, Gray LH. 1955. The histological structure of some human lung cancers and the possible implications for radiotherapy. British Journal of Cancer 9:539-549.
296. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. 1999. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. Journal of Magnetic Resonance Imaging 10:223-232.
297. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF. 1999. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18: 4237-4246.
298. Turetschek K, Floyd E, Shames DM, Roberts TP, Preda A, Novikov V, Corot C, Carter WO, Brasch RC. 2001. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology. Magnetic Resonance in Medicine 45:880-886.
299. Turetschek K, Preda A, Floyd E, Shames DM, Novikov V, Roberts TP, Wood JM, Fu Y, Carter WO, Brasch RC. 2003. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model. European Journal of Nuclear Medicine and Molecular Imaging 30:448-455.
300. Turetschek K, Preda A, Novikov V, Brasch RC, Weinmann HJ, Wunderbaldinger P, Roberts TP. 2004. Tumor microvascular changes in antiangiogenic treatment: Assessment by magnetic resonance contrast media of different molecular weights. Journal of Magnetic Resonance Imaging 20:138-144.
301. Urquidi V, Sloan D, Kawai K, Agarwal D, Woodman AC, Tarin D, Goodison S. 2002. Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clinical Cancer Research 8:61-74.
302. Urtasun RC, Parliament MB, McEwan AJ, Mercer JR, Mannan RH, Wiebe LI, Morin C, Chapman JD. 1996. Measurement of hypoxia in human tumours by non-invasive SPECT imaging of iodoazomycin arabinoside. British Journal of Cancer Supplement 27:S209-S212.
303. van Sluis R, Bhujwalla ZM, Raghunand N, Ballesteros P, Alvarez J, Cerdan S, Galons JP, Gillies RJ. 1999. In vivo imaging of extracellular pH using 1H MRSI. Magnetic Resonance in Medicine 41:743-750.
304. Vaupel P, Briest S, Hockel M. 2002. Hypoxia in breast cancer: Pathogenesis, characterization and biological/therapeutic implications. Wiener Medizinische Wochenschrift 152:334-342.
305. Vaupel P, Kelleher DK, Hockel M. 2001a. Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Seminars in Oncology 28:29-35.
306. 2 tension measurements. Cancer Research 51:3316-3322.
307. Vaupel P, Thews O, Hoeckel M. 2001b. Treatment resistance of solid tumors: Role of hypoxia and anemia. Medical Oncology 18:243-259.
308. 2 extraction is a key parameter determining the oxygenation status of malignant tumors and normal tissues. International Journal of Oncology 22:795-798.
309. Vengellur A, Woods BG, Ryan HE, Johnson RS, LaPres JJ. 2003. Gene expression profiling of the hypoxia signaling pathway in hypoxia-inducible factor 1alpha null mouse embryonic fibroblasts. Gene Expression 11:181-197.
310. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, Treat J. 2000. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. Journal of Clinical Oncology 18:1351-1359.
311. Vordermark D, Brown JM. 2003. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlentherapie und Onkologie 179:801-811.
312. Vujaskovic Z, Rosen EL, Blackwell KL, Jones EL, Brizel DM, Prosnitz LR, Samulski TV, Dewhirst MW. 2003. Ultrasound guided pO2 measurement of breast cancer reoxygenation after neoadjuvant chemotherapy and hyperthermia treatment. International Journal of Hyperthermia 19:498-506.
313. Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, Dicker AP. 2005. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clinical Cancer Research 11:835-842.
314. Wakisaka N, Pagano JS. 2003. Epstein-Barr virus induces invasion and metastasis factors. AntiCancer Research 23:2133-2138.
315. Weinmann HJ, Laniado M, Mutzel W. 1984. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiological Chemistry and Physics in Medical NMR 16:167-172.
316. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. 2004. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Molecular Cancer Therapeutics 3:233-244.
317. Welsh SJ, Powis G. 2003. Hypoxia inducible factor as a cancer drug target. Current Cancer Drug Targets 3:391-405.
318. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. 2003. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Molecular Cancer Therapeutics 2:235-243.
319. Wouters BG, Brown JM. 1997. Cells at intermediate oxygen levels can be more important than the hypoxic fraction in determining tumor response to fractionated radiotherapy. Radiation Research 147:541-550.
320. Wouters BG, Delahoussaye YM, Evans JW, Birrell GW, Dorie MJ, Wang J, MacDermed D, Chiu RK, Brown JM. 2001. Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Research 61:145-152.
321. Wu Y, Denhardt DT, Rittling SR. 2000. Osteopontin is required for full expression of the transformed phenotype by the ras Oncogene. British Journal of Cancer 83:156-163.
322. Yamada K, Inoue D, Matsumoto S, Utsumi H. 2004. In vivo measurement of redox status in streptozotocin-induced diabetic rat using targeted nitroxyl probes. Antioxidants and Redox Signaling 6:605-611.
323. Yamada KI, Kuppusamy P, English S, Yoo J, Irie A, Subramanian S, Mitchell JB, Krishna MC. 2002. Feasibility and assessment of non-invasive in vivo redox status using electron paramagnetic resonance imaging. Acta Radiologica 43:433-440.
324. Yeatman TJ, Chambers AF. 2003. Osteopontin and colon cancer progression. Clinical and Experimental Metastasis 20:85-90.
325. Zagorevskii D, Song M, Breneman C, Yuan Y, Fuchs T, Gates KS, Greenlief CM. 2003. A mass spectrometry study of tirapazamine and its metabolites. insights into the mechanism of metabolic transformations and the characterization of reaction intermediates. Journal of the American Society for Mass Spectrometry 14:881-892.
326. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. 2000. Expression of hypoxia-inducible factor 1alpha in brain tumors: Association with angiogenesis, invasion, and progression. Cancer 88:2606-2618.
327. Zanzonico P, O'donoghue J, Chapman JD, Schneider R, Cai S, Larson S, Wen B, Chen Y, Finn R, Ruan S, Gerweck L, Humm J, Ling C. 2004. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. European Journal of Nuclear Medicine and Molecular Imaging 31:117-128.
328. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. 1986. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. International Journal of Radiation Oncology, Biology, Physics 12:1239-1242.
329. Zhao D, Jiang L, Hahn EW, Mason RP. 2005. Tumor physiological response to combrestatin A4 phosphate assessed by MRI. International Journal of Radiation Oncology, Biology, Physics 62:872-880.
330. Zhao D, Constantinescu A, Chang CH, Hahn EW, Mason RP. 2003a. Correlation of tumor oxygen dynamics with radiation response of the dunning prostate R3327-HI tumor. Radiation Research 159:621-631.
331. Zhao D, Constantinescu A, Hahn EW, Mason RP. 2001. Tumor oxygen dynamics with respect to growth and respiratory challenge: Investigation of the Dunning prostate R3327-HI tumor. Radiation Research 156:510-520.
332. Zhao D, Constantinescu A, Hahn EW, Mason RP. 2002. Differential oxygen dynamics in two diverse Dunning prostate R3327 rat tumor sublines (MAT-Lu and HI) with respect to growth and respiratory challenge. International Journal of Radiation Oncology, Biology, Physics 53:744-756.
333. Zhao D, Jiang L, Mason RP. 2004. Measuring changes in tumor oxygenation. Methods in Enzymology 386:378-418.
334. Zhao D, Ran S, Constantinescu A, Hahn EW, Mason RP. 2003b. Tumor oxygen dynamics: correlation of in vivo MRI with histological findings. Neoplasia 5:308-318.
335. Zhu B, Suzuki K, Goldberg HA, Rittling SR, Denhardt DT, McCulloch CA, Sodek J. 2004. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. Journal of Cell Physiology 198:155-167.
336. Ziemer LS, Evans SM, Kachur AV, Shuman AL, Cardi CA, Jenkins WT, Karp JS, Alavi A, Dolbier WR Jr, Koch CJ. 2003. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. European Journal of Nuclear Medicine and Molecular Imaging 30:259-266.
337. Ziemer LS, Koch CJ, Maity A, Magarelli DP, Horan AM, Evans SM. 2001. Hypoxia and VEGF mRNA expression in human tumors. Neoplasia 3:500-508.